Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Lipoprotein(a) and ischemic cerebrovascular disease in young adults.

View through CrossRef
Serum lipoprotein(a) level is genetically determined and remains almost constant throughout life. Based on this property, we investigated the serum lipoprotein(a) levels of ischemic stroke patients in the chronic stage (mean period after stroke, 27 months) and its relation to the types of ischemic stroke. We measured serum lipoprotein(a) levels in 101 patients with chronic ischemic stroke and 37 normal control subjects, taking the clinical profiles into consideration. Lipoprotein(a) levels in patients with atherothrombotic stroke were 28.0 +/- 19.6 mg/dL (mean +/- SD), which were significantly (P < .01) higher than those in patients with lacunar stroke and in normal control subjects (16.4 +/- 13.5 and 11.7 +/- 10.5 mg/dL, respectively). The lipoprotein(a) levels in patients with atherothrombotic stroke were significantly higher in the subgroup who were a younger age at onset: onset before age 50 years, 35.3 +/- 20.5; onset at age 50 to 59, 35.4 +/- 21.7; onset at age 60 to 69, 17.0 +/- 12.8; and onset at age 70 or older, 16.3 +/- 6.8 mg/dL (P < .01 for onset before age 50 versus 60 to 69 years or 70 years or older; P < .01 for onset at 50 to 59 years versus 60 to 69 years or 70 years or older). Serum lipoprotein(a) was significantly increased (40.2 +/- 20.1 mg/dL) in young adults with atherothrombotic stroke (onset at younger than age 45 years) compared with that in patients older than 45 years (P < .01). We conclude that lipoprotein(a) is a genetic, independent, and critical risk factor for ischemic stroke, especially in young adults.
Ovid Technologies (Wolters Kluwer Health)
Title: Lipoprotein(a) and ischemic cerebrovascular disease in young adults.
Description:
Serum lipoprotein(a) level is genetically determined and remains almost constant throughout life.
Based on this property, we investigated the serum lipoprotein(a) levels of ischemic stroke patients in the chronic stage (mean period after stroke, 27 months) and its relation to the types of ischemic stroke.
We measured serum lipoprotein(a) levels in 101 patients with chronic ischemic stroke and 37 normal control subjects, taking the clinical profiles into consideration.
Lipoprotein(a) levels in patients with atherothrombotic stroke were 28.
0 +/- 19.
6 mg/dL (mean +/- SD), which were significantly (P < .
01) higher than those in patients with lacunar stroke and in normal control subjects (16.
4 +/- 13.
5 and 11.
7 +/- 10.
5 mg/dL, respectively).
The lipoprotein(a) levels in patients with atherothrombotic stroke were significantly higher in the subgroup who were a younger age at onset: onset before age 50 years, 35.
3 +/- 20.
5; onset at age 50 to 59, 35.
4 +/- 21.
7; onset at age 60 to 69, 17.
0 +/- 12.
8; and onset at age 70 or older, 16.
3 +/- 6.
8 mg/dL (P < .
01 for onset before age 50 versus 60 to 69 years or 70 years or older; P < .
01 for onset at 50 to 59 years versus 60 to 69 years or 70 years or older).
Serum lipoprotein(a) was significantly increased (40.
2 +/- 20.
1 mg/dL) in young adults with atherothrombotic stroke (onset at younger than age 45 years) compared with that in patients older than 45 years (P < .
01).
We conclude that lipoprotein(a) is a genetic, independent, and critical risk factor for ischemic stroke, especially in young adults.

Related Results

Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Renal Lipoprotein (a) Metabolism
Renal Lipoprotein (a) Metabolism
The kidney plays a central role in lipoprotein(a) catabolism, acting as a “cemetery for lipoprotein(a)” through uptake, fragmentation, and excretion. Direct human evidence comes fr...
COVID impact on pattern of ischemic heart disease in comparable period
COVID impact on pattern of ischemic heart disease in comparable period
Aim: To compare the impact of COVID-19 on pattern of Ischemic Heart Disease in comparable period by assessing the incidence, severity of symptoms and in-hospital mortality of Ische...
Oral Muvalaplin for Lowering of Lipoprotein(a)
Oral Muvalaplin for Lowering of Lipoprotein(a)
ImportanceMuvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effe...
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
According to epidemiological studies, the leading cause of morbidity, disability and mortality are cerebrovascular diseases, in particular ischemic and hemorrhagic strokes. In rece...
Hematoma Evacuation and Risk of Subsequent Ischemic Stroke and Coronary Ischemic Events: MISTIE III and ATACH-2 Analysis
Hematoma Evacuation and Risk of Subsequent Ischemic Stroke and Coronary Ischemic Events: MISTIE III and ATACH-2 Analysis
BACKGROUND Nontraumatic intracerebral hemorrhage (ICH) especially in deep locations is independently associated with a long-term increased risk of major arterial ...
Pattern of Factors Associated with Obesity in Young Adults of Ischemic Heart Disease
Pattern of Factors Associated with Obesity in Young Adults of Ischemic Heart Disease
Objectives: The objective of studying the pattern of factors associated with obesity in young adults with ischemic heart disease is to identify the various factors that contribute ...

Back to Top